SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer. He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr. Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities.
SystImmune就是家長期處在診療關鍵時期的先進的生物學醫藥化工工廠，悉心于開發代替胃癌治愈的一種新型雙特異形、多特異形免疫免疫抗體及免疫免疫抗體抗癲癇藥物偶聯物（ADCs）。工廠昨天敲定任Jonathan Cheng碩士為SystImmune到任首席霸道總裁生物學官。在添加SystImmune的時候，Cheng碩士在百時美施貴寶出任高級工程師副經理裁兼肺部肉瘤發展壯大方向經理主管，全權管理職責方法抗肺部肉瘤輸油管線的診療售后開發。用此次任，Cheng 碩士接手了Martin Olivo 碩士，前者為去尋找外觀發展壯大方向時機已距離SystImmune。
“I am excited to welcome Dr. Cheng to our leadership team,” said Jie D’Elia, Ph.D., Chief Ｅxecutive Officer of SystImmune. “His global oncology development expertise and in-depth regulatory knowledge will accelerate our efforts to advance SystImmune’s pipeline and transform patient care. On behalf of the SystImmune team, I want to express our deep appreciation to Dr. Martin Olivo for his dedication and contributions to SystImmune. We wish him well in his future endeavors.”
SystImmune頂尖執行工作官Jie D'Elia碩士帶表：“我很喜悅并歡迎辭Cheng碩士加入到.我公司的管理者公司協作。他在歐洲癌腫類藥建設鄰域的靠譜悠長歲月中和對行業中風險防控的難往領悟，將加快和提升SystImmune的輸油管線速度，齊頭并進這一步力促.我公司對患兒治愈的組織變革。我謹指代SystImmune公司協作，向Martin Olivo碩士公戶司的推薦帶表深入的感激。.我公司祝語他在前景一起順暢。”
Dr. Yi Zhu, Chairman of SystImmune, stated “Dr. Cheng brings a wealth of expertise and a remarkable track record in oncology drug development, making him an invaluable addition to SystImmune’s Ｅxecutive leadership team.”
SystImmune副副董事長長朱義碩士生研究生表現：“Cheng碩士生研究生在惡性腫瘤口服藥建設范疇有著充足的職業生活常識和優勝的營業額，他的加盟讓SystImmune一把手專業團隊比較變化。”
Dr. Cheng’s career spans both the pharmaceutical industry and academia, where he has consistently demonstrated exceptional leadership and a passion for advancing cancer treatments. Under Dr. Cheng’s leadership, BMS developed and received regulatory approval for multiple important medicines, including Nivolumab, Ipilimumab, Relatlimab, and Repotrectinib. His strategic vision also enhanced BMS’s internal and collaboration portfolio. Previously, Dr. Cheng served as Therapeutic Area Head of Oncology at Merck and led teams in securing approvals for Pembrolizumab and Lenvatinib across multiple oncology indications. Prior to his career in the pharmaceutical industry, Dr. Cheng had a successful academic career at Fox Chase Cancer Center, where he conducted groundbreaking research as the principal investigator in tumor stromal biology, resulting in over 150 original manuscripts and abstracts. Dr. Cheng received a BS from Marquette University and an MD from the University of Minnesota.
Cheng博后的職業化炫舞時尚夸越醫藥化工服務業和學術討論界，在推動肝癌復發根治地方始終如一能夠 了卓越的官員人本事和友好。在他的官員人下，BMS定制開發并銷售了多樣關鍵性藥劑，收錄Nivolumab、Ipilimumab、Relatlimab和Repotrectinib。他的市場策略遠見卓識，開展了該子公司內部人員產品設備線并且合作協議供水管的相互認知度。在倒入BMS以往，Cheng博后為默沙東肺部癌腫診療理論科學分析總監裁，并官員人開發團隊選取Pembrolizumab和Lenvatinib在若干肺部癌腫適應性癥的銷售應用。在流入醫藥化工服務業以往，Cheng博后在 Fox Chase 肝癌復發主享用順利的學術討論炫舞時尚。他是肺部癌腫機質微物理學的頂尖理論科學助理分析員，通過了再創性的理論科學分析，并養成150 多個默認畫稿和英文論文。Cheng博后提升馬凱特大型學學士本科碩士學位本科碩士學位和明尼蘇達社會分子生物學博后本科碩士學位。
For further information, please contact: info@systimmune.com
如需更高訊息，請連續:info@systimmune.com
About SystImmune
SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development.
至于SystImmune
SystImmune就是一家是在華盛頓州雷德蒙德的始終出現監床檢驗藥理一環節的怪物學醫藥新企業。該新企業細心于使用其成長期的抗癲癇用藥建設APP，建設科技創新的腸癌調理手段，還有雙特女性朋友、多特女性朋友抵抗能力及抵抗能力抗癲癇用藥偶聯物（ADCs）。SystImmune在物理瘤和血夜病域的多監床檢驗藥理疲勞應力測試一環節均持有的管網和系統存儲。除非正去的監床檢驗藥理疲勞應力測試外，新企業還持有的更強的監床檢驗藥理前管網，還有始終出現找到一環節或IND一環節的因素腸癌調理抗癲癇用藥，帶表著新企業在怪物學醫藥建設域的領跑自我實力。
